Larimar Therapeutics, Inc. (LRMR)
| Market Cap | 223.68M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -49.18M |
| Shares Out | 16.00M |
| EPS (ttm) | -3.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 212,960 |
| Open | 11.68 |
| Previous Close | 11.51 |
| Day's Range | 11.39 - 13.78 |
| 52-Week Range | 7.00 - 25.87 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 24.50 (+94.0%) |
| Est. Earnings Date | Nov 9, 2021 |
About LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania.
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for LRMR stock is "Strong Buy." The 12-month stock price forecast is 24.50, which is an increase of 93.98% from the latest price.
News
Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event
BALA CYNWYD, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea...
Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
BALA CYNWYD, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea...
Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress
BALA CYNWYD, Pa., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseas...
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
- Reported positive proof-of-concept and dose response data from Phase 1 program evaluating CTI-1601 in patients with Friedreich's ataxia (FA)
Why Larimar (LRMR) Might Surprise This Earnings Season
Larimar (LRMR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Larimar (LRMR) Upgraded to Buy: Here's Why
Larimar (LRMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Larimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021
BALA CYNWYD, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseas...
Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference
BALA CYNWYD, Pa., June 11, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseas...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investo...
Larimar Stock Craters After FDA Clinical Hold on Friedreich's Ataxia Program
The FDA has instituted a clinical hold on Larimar Therapeutics Inc's (NASDAQ: LRMR) CTI-1601 clinical program as a treatment for Friedreich's Ataxia (FA), a neurodegenerative movement disorder. The clin...
Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Fi...
BALA CYNWYD, Pa., May 25, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich's ataxia ...
Larimar Shares Trade Higher On $95M Capital Raise, CTI-1601's Priority Medicines Tag In Europe
Larimar Therapeutics Inc (NASDAQ: LRMR) has executed a securities purchase agreement to raise gross proceeds of approximately $95 million in a private placement. The proceeds will be used to support the...
Larimar Therapeutics Announces $95 Million Private Placement Financing
BALA CYNWYD, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich's ataxia ...
Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedr...
BALA CYNWYD, Pa., May 20, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich's ataxia ...
Why Is Larimar Therapeutics Stock Plunging Despite Positive CTI-1601 Data?
Larimar Therapeutics Inc (NASDAQ: LRMR) shares are trading lower despite announcing positive topline data from its Phase 1 multiple ascending dose trial evaluating CTI-1601 as a treatment for Friedreich...
Larimar Therapeutics Reports Positive CTI-1601 Data From Friedreich's Ataxia Trial
Larimar Therapeutics Inc (NASDAQ: LRMR) has announced topline data from its Phase 1 multiple ascending dose trial evaluating CTI-1601 as a treatment for Friedreich's Ataxia (FA). FA is a genetic, progre...
Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxi...
BALA CYNWYD, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich's ataxia ...
Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results
- Topline data from placebo-controlled Phase 1 program in Friedreich's ataxia patients to be announced tomorrow, May 11, 2021- Management to discuss during webcast and conference call at 8 a.m. ET
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
- Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020 - Company signed $80 million in private placement financing with biotechnology focused i...
Zafgen To Explore Strategic Options, With No Near-Term Resolution For Diabetes Drug
Clinical-stage biopharma companies often face the risk of running out of cash reserves to fund their operations until they can push their investigational assets out of the clinics into the commercializa...
Zafgen to Explore Strategic Alternatives
Preliminary results from in vivo animal study not expected to warrant near-term resolution of clinical hold for ZGN-1061 Preliminary results from in vivo animal study not expected to warrant near-term r...
Micro-Cap Biotech Zafgen Plunges To Record Low: What You Need To Know
Shares of Zafgen Inc (NASDAQ: ZFGN) were tumbling below the psychological barrier of $2 in Thursday's session.
The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug
Zafgem said it has planned to suspend to file an investigational new drug application, or IND, for its ZGN-1258, which it's evaluating for rare metabolic disorders including Prader-Willi syndrome.